FDA OKs Teva NDA for Olanzapine Extended-Release TEV-'749 Once-Monthly for Schizophrenia

 

• Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation¹
• If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations¹
• Teva is committed to advancing this innovative treatment option and further building on its differentiated LAI franchise and scientific leadership in complex neurological conditions as it drives forward its Pivot to Growth strategy

https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/U-S--Food-and-Drug-Administration-FDA-Accepts-Tevas-New-Drug-Application-NDA-for-Olanzapine-Extended-Release-Injectable-Suspension-TEV-749-for-the-Once-Monthly-Treatment-of-Schizophrenia-in-Adults/default.aspx